Cargando…
Extended plasma half-life of albumin-binding domain fused human IgA upon pH-dependent albumin engagement of human FcRn in vitro and in vivo
Albumin has a serum half-life of 3 weeks in humans. This feature can be used to improve the pharmacokinetics of shorter-lived biologics. For instance, an albumin-binding domain (ABD) can be used to recruit albumin. A prerequisite for such design is that the ABD-albumin interaction does not interfere...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7954421/ https://www.ncbi.nlm.nih.gov/pubmed/33691596 http://dx.doi.org/10.1080/19420862.2021.1893888 |
_version_ | 1783664075813683200 |
---|---|
author | Mester, Simone Evers, Mitchell Meyer, Saskia Nilsen, Jeannette Greiff, Victor Sandlie, Inger Leusen, Jeanette Andersen, Jan Terje |
author_facet | Mester, Simone Evers, Mitchell Meyer, Saskia Nilsen, Jeannette Greiff, Victor Sandlie, Inger Leusen, Jeanette Andersen, Jan Terje |
author_sort | Mester, Simone |
collection | PubMed |
description | Albumin has a serum half-life of 3 weeks in humans. This feature can be used to improve the pharmacokinetics of shorter-lived biologics. For instance, an albumin-binding domain (ABD) can be used to recruit albumin. A prerequisite for such design is that the ABD-albumin interaction does not interfere with pH-dependent binding of albumin to the human neonatal Fc receptor (FcRn), as FcRn acts as the principal regulator of the half-life of albumin. Thus, there is a need to know how ABDs act in the context of fusion partners and human FcRn. Here, we studied the binding and transport properties of human immunoglobulin A1 (IgA1), fused to a Streptococcus protein G-derived engineered ABD, in in vitro and in vivo systems harboring human FcRn. IgA has great potential as a therapeutic protein, but its short half-life is a major drawback. We demonstrate that ABD-fused IgA1 binds human FcRn pH-dependently and is rescued from cellular degradation in a receptor-specific manner in the presence of albumin. This occurs when ABD is fused to either the light or the heavy chain. In human FcRn transgenic mice, IgA1-ABD in complex with human albumin, gave 4-6-fold extended half-life compared to unmodified IgA1, where the light chain fusion showed the longest half-life. When the heavy chain-fused protein was pre-incubated with an engineered human albumin with improved FcRn binding, cellular rescue and half-life was further enhanced. Our study reveals how an ABD, which does not interfere with albumin binding to human FcRn, may be used to extend the half-life of IgA. Abbreviations: ABD - Albumin binding domain, ADA – anti-drug-antibodies, ADCC - Antibody-dependent cellular cytotoxicity, ELISA - Enzyme-linked Immunosorbent assay, FcαRI - Fcα receptor, FcγR - Fcγ receptor, FcRn - The neonatal Fc receptor, GST - Glutathione S-transferase, HC - Heavy chain, HERA - Human endothelial cell-based recycling assay, Her2 - Human epidermal growth factor 2, HMEC - Human microvascular endothelial cells, IgG - Immunoglobulin G, IgA - Immunoglobulin A, LC - Light chain, QMP - E505Q/T527M/K573P, WT - Wild type |
format | Online Article Text |
id | pubmed-7954421 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Taylor & Francis |
record_format | MEDLINE/PubMed |
spelling | pubmed-79544212021-03-23 Extended plasma half-life of albumin-binding domain fused human IgA upon pH-dependent albumin engagement of human FcRn in vitro and in vivo Mester, Simone Evers, Mitchell Meyer, Saskia Nilsen, Jeannette Greiff, Victor Sandlie, Inger Leusen, Jeanette Andersen, Jan Terje MAbs Report Albumin has a serum half-life of 3 weeks in humans. This feature can be used to improve the pharmacokinetics of shorter-lived biologics. For instance, an albumin-binding domain (ABD) can be used to recruit albumin. A prerequisite for such design is that the ABD-albumin interaction does not interfere with pH-dependent binding of albumin to the human neonatal Fc receptor (FcRn), as FcRn acts as the principal regulator of the half-life of albumin. Thus, there is a need to know how ABDs act in the context of fusion partners and human FcRn. Here, we studied the binding and transport properties of human immunoglobulin A1 (IgA1), fused to a Streptococcus protein G-derived engineered ABD, in in vitro and in vivo systems harboring human FcRn. IgA has great potential as a therapeutic protein, but its short half-life is a major drawback. We demonstrate that ABD-fused IgA1 binds human FcRn pH-dependently and is rescued from cellular degradation in a receptor-specific manner in the presence of albumin. This occurs when ABD is fused to either the light or the heavy chain. In human FcRn transgenic mice, IgA1-ABD in complex with human albumin, gave 4-6-fold extended half-life compared to unmodified IgA1, where the light chain fusion showed the longest half-life. When the heavy chain-fused protein was pre-incubated with an engineered human albumin with improved FcRn binding, cellular rescue and half-life was further enhanced. Our study reveals how an ABD, which does not interfere with albumin binding to human FcRn, may be used to extend the half-life of IgA. Abbreviations: ABD - Albumin binding domain, ADA – anti-drug-antibodies, ADCC - Antibody-dependent cellular cytotoxicity, ELISA - Enzyme-linked Immunosorbent assay, FcαRI - Fcα receptor, FcγR - Fcγ receptor, FcRn - The neonatal Fc receptor, GST - Glutathione S-transferase, HC - Heavy chain, HERA - Human endothelial cell-based recycling assay, Her2 - Human epidermal growth factor 2, HMEC - Human microvascular endothelial cells, IgG - Immunoglobulin G, IgA - Immunoglobulin A, LC - Light chain, QMP - E505Q/T527M/K573P, WT - Wild type Taylor & Francis 2021-03-10 /pmc/articles/PMC7954421/ /pubmed/33691596 http://dx.doi.org/10.1080/19420862.2021.1893888 Text en © 2021 The Author(s). Published with license by Taylor & Francis Group, LLC. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Report Mester, Simone Evers, Mitchell Meyer, Saskia Nilsen, Jeannette Greiff, Victor Sandlie, Inger Leusen, Jeanette Andersen, Jan Terje Extended plasma half-life of albumin-binding domain fused human IgA upon pH-dependent albumin engagement of human FcRn in vitro and in vivo |
title | Extended plasma half-life of albumin-binding domain fused human IgA upon pH-dependent albumin engagement of human FcRn in vitro and in vivo |
title_full | Extended plasma half-life of albumin-binding domain fused human IgA upon pH-dependent albumin engagement of human FcRn in vitro and in vivo |
title_fullStr | Extended plasma half-life of albumin-binding domain fused human IgA upon pH-dependent albumin engagement of human FcRn in vitro and in vivo |
title_full_unstemmed | Extended plasma half-life of albumin-binding domain fused human IgA upon pH-dependent albumin engagement of human FcRn in vitro and in vivo |
title_short | Extended plasma half-life of albumin-binding domain fused human IgA upon pH-dependent albumin engagement of human FcRn in vitro and in vivo |
title_sort | extended plasma half-life of albumin-binding domain fused human iga upon ph-dependent albumin engagement of human fcrn in vitro and in vivo |
topic | Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7954421/ https://www.ncbi.nlm.nih.gov/pubmed/33691596 http://dx.doi.org/10.1080/19420862.2021.1893888 |
work_keys_str_mv | AT mestersimone extendedplasmahalflifeofalbuminbindingdomainfusedhumanigauponphdependentalbuminengagementofhumanfcrninvitroandinvivo AT eversmitchell extendedplasmahalflifeofalbuminbindingdomainfusedhumanigauponphdependentalbuminengagementofhumanfcrninvitroandinvivo AT meyersaskia extendedplasmahalflifeofalbuminbindingdomainfusedhumanigauponphdependentalbuminengagementofhumanfcrninvitroandinvivo AT nilsenjeannette extendedplasmahalflifeofalbuminbindingdomainfusedhumanigauponphdependentalbuminengagementofhumanfcrninvitroandinvivo AT greiffvictor extendedplasmahalflifeofalbuminbindingdomainfusedhumanigauponphdependentalbuminengagementofhumanfcrninvitroandinvivo AT sandlieinger extendedplasmahalflifeofalbuminbindingdomainfusedhumanigauponphdependentalbuminengagementofhumanfcrninvitroandinvivo AT leusenjeanette extendedplasmahalflifeofalbuminbindingdomainfusedhumanigauponphdependentalbuminengagementofhumanfcrninvitroandinvivo AT andersenjanterje extendedplasmahalflifeofalbuminbindingdomainfusedhumanigauponphdependentalbuminengagementofhumanfcrninvitroandinvivo |